keyword
MENU ▼
Read by QxMD icon Read
search

Nab-paclitaxel

keyword
https://www.readbyqxmd.com/read/28315068/efficacy-and-safety-of-nab-paclitaxel-125%C3%A2-mg-m-2-and-nab-paclitaxel-150%C3%A2-mg-m-2-compared-to-paclitaxel-in-early-high-risk-breast-cancer-results-from-the-neoadjuvant-randomized-geparsepto-study-gbg-69
#1
Jenny Furlanetto, Christian Jackisch, Michael Untch, Andreas Schneeweiss, Sabine Schmatloch, Bahriye Aktas, Carsten Denkert, Hermann Wiebringhaus, Sherko Kümmel, Mathias Warm, Stefan Paepke, Marianne Just, Claus Hanusch, John Hackmann, Jens Uwe Blohmer, Michael Clemens, Serban Dan Costa, Bernd Gerber, Valentina Nekljudova, Sibylle Loibl, Gunter von Minckwitz
PURPOSE: The GeparSepto study demonstrated that the use of nab-paclitaxel instead of paclitaxel prior to anthracycline-based chemotherapy could lead to a significantly increased pCR rate, especially in the triple negative subpopulation. We report efficacy and safety for patients treated with two different doses of nab-paclitaxel in comparison to weekly solvent-formulated paclitaxel. METHODS: Patients were treated for 12 weeks with either intravenous nab-paclitaxel 150 mg/m(2) (nP150) weekly, after study amendment 125 mg/m(2) (nP125) weekly or solvent-based paclitaxel 80 mg/m(2) (P80) weekly followed by epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) on day 1 for four 3-week cycles...
March 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28304139/efficacy-and-safety-of-weekly-intravenous-nanoparticle-albumin-bound-paclitaxel-for-non-small-cell-lung-cancer-patients-who-have-failed-at-least-two-prior-systemic-treatments
#2
Jianchun Duan, Yueqin Hao, Rui Wan, Sifan Yu, Hua Bai, Tongtong An, Jun Zhao, Zhijie Wang, Minglei Zhuo, Jie Wang
BACKGROUND: The study was conducted to evaluate the efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) treatment in patients with advanced non-small-cell lung cancer (NSCLC) who have undergone multi-line therapy, and to investigate the association of secreted protein acidic and rich in cysteine (SPARC) expression status with clinical outcome. METHODS: Sixty-four patients who received NAB-paclitaxel treatment (130 mg/m(2) on days 1 and 8 of a 21 day cycle) as third line or further systemic treatment from 1 May 2011 to 30 June 2014 were included in this retrospective analysis...
March 17, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28303435/systemic-combination-chemotherapy-in-elderly-pancreatic-cancer-a-review
#3
REVIEW
Gwenalyn Garcia, Marcel Odaimi
PURPOSE: In recent years, significant progress in survival has been achieved using systemic combination chemotherapy in patients with pancreatic cancer. However, the elderly are largely underrepresented in clinical trials, and gains made from these may not necessarily apply to this important subgroup of patients. We review the currently available data regarding contemporary combination chemotherapy regimens, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, nanoliposomal irinotecan plus 5-fluorouracil and leucovorin, and gemcitabine plus capecitabine, in elderly pancreatic cancer patients...
March 16, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28299752/therapeutic-implications-of-molecular-subtyping-for-pancreatic-cancer
#4
REVIEW
Michael J Pishvaian, Jonathan R Brody
The prognosis of metastatic pancreatic adenocarcinoma has recently begun to improve. In the last several years, first-line therapy with gemcitabine plus nab-paclitaxel or a regimen of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has boosted the median overall survival (OS) duration to 8.5 months and 11 months, respectively, in patients with metastatic pancreatic cancer, compared with a historic OS of only 6 months prior to 2011. Moreover, sequencing these two regimens improved median OS to an unprecedented 18 months...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28293715/a-phase-1-study-of-gemcitabine-nab-paclitaxel-s-1-gas-combination-neoadjuvant-chemotherapy-for-patients-with-locally-advanced-pancreatic-adenocarcinoma
#5
Naru Kondo, Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Naoya Nakagawa, Shinya Takahashi, Hiroki Ohge, Taijiro Sueda
PURPOSE: To determine a recommended dose for a biweekly combination neoadjuvant chemotherapy including gemcitabine, nab-paclitaxel, and S-1 (GAS) for patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). METHODS: Patients with borderline resectable or unresectable LAPC without distant metastasis were eligible for this study. The planned dosages of gemcitabine (mg/m(2), day 1), nab-paclitaxel (mg/m(2), day 1), and S-1 (mg/day, days 1-7) were 800/100/60-100 at level 1, and 1000/125/60-100 at level 2...
March 14, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28287120/optimizing-non-invasive-radiofrequency-hyperthermia-treatment-for-improving-drug-delivery-in-4t1-mouse-breast-cancer-model
#6
Matthew J Ware, Martyna Krzykawska-Serda, Jason Chak-Shing Ho, Jared Newton, Sarah Suki, Justin Law, Lam Nguyen, Vazrik Keshishian, Maciej Serda, Kimberly Taylor, Steven A Curley, Stuart J Corr
Interactions of high-frequency radio waves (RF) with biological tissues are currently being investigated as a therapeutic platform for non-invasive cancer hyperthermia therapy. RF delivers thermal energy into tissues, which increases intra-tumoral drug perfusion and blood-flow. Herein, we describe an optical-based method to optimize the short-term treatment schedules of drug and hyperthermia administration in a 4T1 breast cancer model via RF, with the aim of maximizing drug localization and homogenous distribution within the tumor microenvironment...
March 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28286977/comparison-of-treatment-patterns-resource-utilization-and-cost-of-care-in-patients-with-metastatic-pancreatic-cancer-treated-with-first-line-nab-paclitaxel-plus-gemcitabine-or-folfirinox
#7
George P Kim, Monika F Parisi, Manish B Patel, Corey L Pelletier, Kathy W Belk
BACKGROUND: We compared real-world treatment patterns, resource utilization, and cost of care for patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel + gemcitabine or FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin). METHODS: This was a retrospective study of inpatient and hospital-based outpatient data in the United States. Primary endpoints included median time to treatment discontinuation (TTD) and total cost of care per patient per month...
March 13, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28256066/a-randomized-phase-ii-study-of-nab-paclitaxel-as-first-line-chemotherapy-in-patients-with-her2-negative-metastatic-breast-cancer
#8
Kenji Tamura, Kenichi Inoue, Norikazu Masuda, Shintaro Takao, Masahiro Kashiwaba, Yutaka Tokuda, Hiroji Iwata, Naohito Yamamoto, Kenjiro Aogi, Toshiaki Saeki, Takahiro Nakayama, Nobuaki Sato, Tatsuya Toyama, Takanori Ishida, Hitoshi Arioka, Mitsue Saito, Shinji Ohno, Hideko Yamauchi, Kimito Yamada, Junichiro Watanabe, Hiroshi Ishiguro, Yasuhiro Fujiwara
Weekly administration of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has been shown to be a safe and effective treatment for metastatic breast cancer (MBC) in clinical studies. We conducted a multicenter, randomized, open-label phase II study to compare the efficacy and safety of weekly nab-paclitaxel and docetaxel in Japanese patients with human epidermal growth factor receptor 2-negative MBC. The primary endpoint was progression-free survival (PFS). Patients were randomized to receive nab-paclitaxel (150 mg/m(2) nab-paclitaxel once per week for 3 of 4 weeks; n = 100) or docetaxel (75 mg/m(2) docetaxel every 3 weeks; n = 100)...
March 3, 2017: Cancer Science
https://www.readbyqxmd.com/read/28253828/emerging-protein-kinase-inhibitors-for-treating-pancreatic-cancer
#9
Junji Furuse, Fumio Nagashima
Pancreatic cancer, the incidence and mortality of which are increasing around the world, has the most dismal prognosis among the commonly encountered cancers. Systemic chemotherapy plays an important role in the treatment of patients with pancreatic cancer, and development of more effective chemotherapies is being sought. Areas covered: This review article provides a summary about protein kinase inhibitors that have been investigated for the treatment of pancreatic cancer, not only existing agents targeting RAS, EGFR, VEGFR, MEK, etc...
March 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/28247168/high-penetration-of-paclitaxel-in-abdominal-wall-of-rabbits-after-hyperthermic-intraperitoneal-administration-of-nab-paclitaxel-compared-to-standard-paclitaxel-formulation
#10
Federico Coccolini, Fabio Acocella, Lavinia Morosi, Stefano Brizzola, Matteo Ghiringhelli, Marco Ceresoli, Enrico Davoli, Luca Ansaloni, Maurizio D'Incalci, Massimo Zucchetti
PURPOSE: Paclitaxel (PTX) is currently used in combination with cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis. Albumin-bound PTX is a promising new drug for HIPEC because of its easy solubility in aqueous perfusion medium and possibly because of the tendency of albumin to cross physiological barriers and accumulate in tumor tissue. METHODS: We tested the feasibility of using nab-paclitaxel in rabbits treated by HIPEC for 60 min compared with the classical formulation at an equivalent PTX dose...
February 28, 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/28223678/-conversion-surgery-for-initially-unresectable-locally-advanced-pancreatic-cancer-following-gemcitabine-plus-nab-paclitaxel-a-case-report
#11
Shuji Nakamoto, Ryo Nishiyama, Takayoshi Kaneda, Mitsuo Yokota, Hiroshi Kawamata, Hiroshi Tajima, Takashi Kaizu, Yusuke Kumamoto, Hiroshi Yamauchi, Kosuke Okuwaki, Tomohisa Iwai, Hiroshi Imaizumi, Erina Suzuki, Atsuko Hara, Masaaki Ichinoe, Mitsuhiro Kida, Masahiko Watanabe
We report a case of unresectable locally advanced pancreatic cancer successfully resected after gemcitabine(GEM)plus nab-paclitaxel(PTX)treatment. A 68-year-old man was referred to our institution with jaundice. We diagnosed pancreatic head cancer using computed tomography(CT)and endoscopic retrograde cholangiopancreatography. We initially diagnosed it as locally advanced unresectable pancreatic cancer because of extensive invasion to the portal vein. GEM plus nab- PTX was administered to the patient as systemic chemotherapy...
February 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28203300/a-modified-regimen-of-biweekly-gemcitabine-and-nab-paclitaxel-in-patients-with-metastatic-pancreatic-cancer-is-both-tolerable-and-effective-a-retrospective-analysis
#12
Daniel H Ahn, Kavya Krishna, Marlo Blazer, Joshua Reardon, Lai Wei, Christina Wu, Kristen K Ciombor, Anne M Noonan, Sameh Mikhail, Tanios Bekaii-Saab
BACKGROUND: Treatment with nab-paclitaxel with gemcitabine demonstrates a survival advantage when compared with single-agent gemcitabine. However, the combination is associated with significant toxicities, leading to a high rate of drug discontinuation. We implemented a modified regimen of gemcitabine and nab-paclitaxel (mGNabP) in an attempt to minimize toxicities while maintaining efficacy. METHODS: A total of 79 evaluable patients with metastatic pancreatic adenocarcinoma (mPC) treated with a modified regimen of gemcitabine (1000 mg/m(2)) and nab-paclitaxel (125 mg/m(2)) on days 1, 15 of every 28-day cycle were identified from our prospective database...
February 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28203092/nab-paclitaxel-plus-gemcitabine-for-metastatic-pancreatic-cancer-a-subgroup-analysis-of-the-western-european-cohort-of-the-mpact-trial
#13
Josep Tabernero, Volker Kunzmann, Werner Scheithauer, Michele Reni, Jack Shiansong Li, Stefano Ferrara, Kamel Djazouli
PURPOSE: The global Phase III MPACT trial demonstrated superior efficacy of nab-paclitaxel plus gemcitabine over gemcitabine alone as first-line treatment for metastatic pancreatic cancer. Region was a randomization stratification factor in the MPACT trial. This subgroup analysis of MPACT examined efficacy and safety of patients treated in Western Europe. PATIENTS AND METHODS: Patients received nab-paclitaxel plus gemcitabine or gemcitabine alone as first-line treatment for metastatic pancreatic cancer as previously described...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28186974/a-notch-sensitive-upar-regulated-oncolytic-adenovirus-effectively-suppresses-pancreatic-tumor-growth-and-triggers-synergistic-anticancer-effects-with-gemcitabine-and-nab-paclitaxel
#14
Ana Mato-Berciano, Giulia Raimondi, Maria Victoria Maliandi, Ramon Alemany, Lluis Montoliu, Cristina Fillat
Notch signaling pathway is an embryonic program that becomes reactivated in pancreatic cancer and contributes to cancer stem cell (CSC) maintenance. We explored the concept of oncolytic adenoviral activity in response to Notch activation signaling, in the context of a chimeric promoter with uPAR regulatory sequences, as a strategy to drive its activity in neoplastic and CSC. We explored the advantages of a chemo-virotherapy approach based on synergistic combinations. Regulatory sequences recognized by the transcriptional factor CSL upstream a minimal uPAR promoter were engineered in adenoviral vectors and in the oncolytic adenovirus AdNuPARmE1A...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28179342/phase-i-study-of-nab-paclitaxel-plus-gemcitabine-as-neoadjuvant-therapy-for-borderline-resectable-pancreatic-cancer
#15
Ken-Ichi Okada, Seiko Hirono, Manabu Kawai, Motoki Miyazawa, Atsushi Shimizu, Yuji Kitahata, Masaki Ueno, Shinya Hayami, Hiroki Yamaue
BACKGROUND/AIM: The aim of this study was to investigate the safety and feasibility of neoadjuvant nab-paclitaxel plus gemcitabine therapy for patients with borderline resectable pancreatic carcinoma (BRPC). PATIENTS AND METHODS: The study was a prospective single-center phase I trial for patients with BRPC. The primary endpoint was the toxicity, and secondary endpoints were the resection rate, the R0 resection rate and quality of life (QOL) regarding the peripheral sensory neuropathy (PSN)...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28163086/long-term-survival-outcomes-with-intravesical-nanoparticle-albumin-bound-paclitaxel-for-recurrent-nonmuscle-invasive-bladder-cancer-after-previous-bacillus-calmette-gu%C3%A3-rin-therapy
#16
Dennis J Robins, Wilson Sui, Justin T Matulay, Rashed Ghandour, Christopher B Anderson, G Joel DeCastro, James M McKiernan, John K Lattimer
OBJECTIVE: To report long-term follow up results of a phase II trial of salvage intravesical nanoparticle albumin bound (nab)-paclitaxel for patients with recurrent non-muscle invasive bladder cancer after previous intravesical Bacillus Calmette-Guérin (BCG) therapy. METHODS: This was a phase II trial investigating the use of intravesical nab-paclitaxel in patients with recurrent Tis, Ta, and T1 urothelial carcinoma who failed at least one prior induction course of intravesical BCG...
February 2, 2017: Urology
https://www.readbyqxmd.com/read/28152884/comparative-effectiveness-of-early-line-nab-paclitaxel-nab-p-versus-eribulin-in-patients-pts-with-metastatic-breast-cancer-mbc-a-u-s-real-world-analysis
#17
Monika Parisi, Quanhong Ni, Si Yeon Park, Claudio Faria
293 Background: In a phase III study in MBC, nab-P demonstrated anti-tumor activity across lines of therapy. Eribulin is indicated for the treatment (Tx) of MBC in pts who have previously received ≥ 2 chemotherapeutic regimens. This analysis evaluated Tx patterns and effectiveness of nab-P and eribulin in pts with MBC in a real-world community-based setting. METHODS: A retrospective cohort study was performed using fully de-identified data from a US electronic medical record platform of 1300 community oncology physicians...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152807/outcomes-by-schedule-and-line-of-therapy-in-patients-pts-with-metastatic-breast-cancer-mbc-treated-with-nab-paclitaxel-nab-p-a-u-s-retrospective-community-based-real-world-cohort-analysis
#18
Sotirios G Stergiopoulos, Rick Hippert, Robyn K Harrell, Janet L Espirito, Peg Squier, Amy Ko
86 Background: In a phase III study in MBC, nab-P showed activity across lines of therapy. nab-P is approved for MBC at 260 mg/m(2) every 3 weeks (q3w). This analysis evaluated outcomes with use of nab-P in MBC by schedule and line of therapy in a U.S. community setting. METHODS: A multicenter, retrospective cohort analysis was conducted using iKnowMed electronic health record data and electronic medical chart review of women with ≥ 5 visits to a site in the US Oncology Network. Vital status was supplemented by the Social Security Death Index...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152775/quality-of-life-qol-by-response-an-interim-analysis-of-patients-pts-with-squamous-scc-nsclc-treated-with-nab-paclitaxel-carboplatin-nab-p-c-induction-therapy-in-the-phase-iii-abound-sqm-study
#19
Vera Hirsh, Katayoun Amiri, Amy Ko, Jeanna L Knoble, Melissa Lynne Johnson, Robert M Jotte, Michael McCleod, Teng Jin Ong, Ray D Page, David R Spigel, Howard Jack West
63 Background: The correlation of radiological response and pt-reported outcomes (PROs) in advanced NSCLC remains underreported. This interim analysis evaluated QoL by response (RECIST v1.1) in SCC NSCLC pts treated with nab-P/C during the induction part of the ABOUND.sqm study. METHODS: In the ongoing phase III ABOUND.sqm study, pts with advanced SCC NSCLC are treated with first-line nab-P 100 mg/m(2) d 1, 8, 15 and C AUC 6 mg•min/mL d 1 (21-d cycles) for 4 cycles (induction). Pts not progressing are randomized 2:1 to maintenance nab-P 100 mg/m(2)d 1 and 8 of each 21-d cycle + best supportive care (BSC) or BSC alone until progression...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152774/quality-of-life-qol-in-patients-pts-with-squamous-scc-nsclc-treated-with-nab-paclitaxel-with-carboplatin-nab-p-c-induction-therapy-interim-analysis-of-the-phase-iii-abound-sqm-study
#20
Corey J Langer, Robert M Jotte, Edward S Kim, Amy Ko, Teng Jin Ong, Mark A Socinski, Peter Staib, Nataliya Trunova, David R Spigel
64 Background: Recent data on QoL in pts with advanced NSCLC treated with platinum-doublets are limited. This interim analysis evaluated QoL in pts with SCC NSCLC treated with nab-P/C during the induction part of the ABOUND.sqm study. METHODS: In the ongoing phase III ABOUND.sqm study, pts with advanced SCC NSCLC are treated with first-line nab-P 100 mg/m(2) d 1, 8, 15 and C AUC 6 mg•min/mL d 1 (21-d cycles) for 4 cycles (induction). Pts not progressing after 4 cycles are randomized 2:1 to maintenance nab-P 100 mg/m(2)d 1 and 8 of each 21-d cycle + best supportive care (BSC) or BSC alone until progression...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
18258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"